IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.072
AS - Asia 3.108
EU - Europa 1.344
SA - Sud America 616
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 6
Totale 9.215
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.947
SG - Singapore 1.511
CN - Cina 741
IT - Italia 641
BR - Brasile 482
VN - Vietnam 306
IN - India 277
SE - Svezia 202
GB - Regno Unito 128
DE - Germania 111
CA - Canada 82
HK - Hong Kong 63
AR - Argentina 51
FI - Finlandia 48
BD - Bangladesh 33
MX - Messico 28
RO - Romania 28
EC - Ecuador 26
IQ - Iraq 25
ID - Indonesia 23
RU - Federazione Russa 23
NL - Olanda 22
PL - Polonia 21
UA - Ucraina 21
CL - Cile 20
JP - Giappone 17
FR - Francia 16
ES - Italia 15
EU - Europa 15
CZ - Repubblica Ceca 13
EG - Egitto 13
PK - Pakistan 13
PY - Paraguay 13
TR - Turchia 13
ZA - Sudafrica 13
VE - Venezuela 11
JO - Giordania 10
AT - Austria 9
IR - Iran 9
AE - Emirati Arabi Uniti 8
MY - Malesia 7
UZ - Uzbekistan 7
KE - Kenya 6
LT - Lituania 6
SA - Arabia Saudita 6
AU - Australia 5
CH - Svizzera 5
CO - Colombia 5
GR - Grecia 5
NP - Nepal 5
YE - Yemen 5
DO - Repubblica Dominicana 4
EE - Estonia 4
HR - Croazia 4
IE - Irlanda 4
IL - Israele 4
MA - Marocco 4
PH - Filippine 4
TN - Tunisia 4
DZ - Algeria 3
KZ - Kazakistan 3
PA - Panama 3
PE - Perù 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KW - Kuwait 2
LB - Libano 2
NO - Norvegia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
CY - Cipro 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NR - Nauru 1
PR - Porto Rico 1
PT - Portogallo 1
Totale 9.211
Salva come PNG Salva come JPEG
Città #
San Jose 858
Singapore 496
Chandler 388
Ashburn 379
Santa Clara 249
Dallas 234
Hefei 225
Bengaluru 219
Milan 191
Lawrence 189
Princeton 189
Beijing 168
Catanzaro 139
Ho Chi Minh City 131
Wilmington 106
Chicago 90
London 90
Munich 84
Hong Kong 63
Hanoi 60
Des Moines 57
Ottawa 47
São Paulo 46
Boardman 36
Turku 34
Los Angeles 29
Rio de Janeiro 26
Shanghai 24
Haiphong 22
Brooklyn 20
Redwood City 20
Rome 20
Warsaw 19
New York 18
Council Bluffs 16
Guangzhou 16
San Francisco 15
Helsinki 14
Horia 14
Pune 14
The Dalles 14
Da Nang 13
Montreal 13
Naples 13
Norwalk 13
Phoenix 13
Olomouc 12
Stockholm 12
Baghdad 11
Bari 11
Boston 11
Hanover 10
Manchester 10
Redmond 10
Timisoara 10
Amman 9
Cosenza 9
Curitiba 9
Mexico City 9
Tokyo 9
Chennai 8
Columbus 8
Dhaka 8
Porto Alegre 8
Quito 8
Reggio Calabria 8
Ann Arbor 7
Biên Hòa 7
Charlotte 7
Guayaquil 7
Jiaxing 7
Johannesburg 7
Lamezia Terme 7
Orem 7
Ovada 7
San Nicola Manfredi 7
Santiago 7
Settingiano 7
Shenzhen 7
Tashkent 7
Amsterdam 6
Atlanta 6
Belo Horizonte 6
Nairobi 6
Palermo 6
Parma 6
Salvador 6
Thái Bình 6
Uberlândia 6
West Jordan 6
Andover 5
Ankara 5
Augusta 5
Aversa 5
Campinas 5
Caracas 5
Caserta 5
Contagem 5
Florianópolis 5
Istanbul 5
Totale 5.532
Salva come PNG Salva come JPEG
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 98
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 85
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 85
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 82
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 81
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 80
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 77
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 72
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 72
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 71
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 71
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 70
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 69
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 69
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 68
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 67
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 67
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 66
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 66
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 65
In Vitro Silencing of lncRNAs Using LNA GapmeRs 65
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 65
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 64
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 63
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 62
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 61
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 61
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 61
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 61
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 59
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 59
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 59
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 59
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 59
Contribution of PKB/AKT signaling to thyroid cancer 59
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 59
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 58
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 58
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 58
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 56
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 56
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 56
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 56
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 56
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 56
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 55
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 55
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 55
The non-coding RNA landscape of plasma cell dyscrasias 55
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 54
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 54
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 54
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 53
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 53
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 53
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 52
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 52
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 52
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 52
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 52
ZINC FINGER PROTEIN 521 (EHZF/ZNF521) ANTAGONIZES EARLY B-CELL FACTOR 1 AND MODULATES THE B-LYMPHOID DIFFERENTIATION OF PRIMARY HEMATOPOIETIC PROGENITORS 51
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 51
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 51
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 51
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity (CO-FIRST AUTHOR) 50
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 50
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 50
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 50
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 49
Biological Insights into Myeloma and Other B Cell Malignancies 49
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 48
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 48
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 48
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 48
Phoenixin-14: detection and novel physiological implications in cardiac modulation and cardioprotection 48
Protective role of GPER agonist g-1 on cardiotoxicity induced by doxorubicin 48
Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma 47
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 47
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 47
Palmitate-Induced Cardiac Lipotoxicity Is Relieved by the Redox-Active Motif of SELENOT through Improving Mitochondrial Function and Regulating Metabolic State 47
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 46
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 46
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 45
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 44
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 44
Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma 44
Contribution of PKB/AKT signaling to thyroid cancer 43
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations 43
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 43
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 43
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 43
null 43
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 42
Totale 5.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.948
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.948
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021144 0 0 0 0 0 0 0 0 0 45 72 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20252.129 321 95 65 58 151 302 44 51 266 130 214 432
2025/20264.488 264 494 445 773 518 181 604 275 639 295 0 0
Totale 9.464